OncoMatch/Clinical Trials/Neuroblastoma
Neuroblastoma Clinical Trials
OncoMatch filters Neuroblastoma trials by the molecular markers that determine eligibility — MYCN, ALK, PHOX2B, and more. Enter your biomarker results to see only the trials you may qualify for.
Compare eligibility criteriaTop recruiting Neuroblastoma trials
Ranked by phase and number of US sites. See all trials matched to your profile →
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
National Cancer Institute (NCI)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Children's Oncology Group
Induction Chemoimmunotherapy for Patients With High-risk Neuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
18F-DOPA II - PET Imaging Optimization
University of Alberta
Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Cancer Research UK
How OncoMatch finds Neuroblastoma trials for you
AI reads the protocol
Every Neuroblastoma trial on ClinicalTrials.gov has eligibility criteria written for regulators. OncoMatch uses large language models to extract the structured requirements — biomarkers, stage, prior therapy, and more — from that text.
You enter your results
Select Neuroblastoma and mark your biomarker results — MYCN, ALK, PHOX2B — as positive, negative, or not tested. Your data never leaves your device.
See only relevant trials
Results filter instantly. Each trial shows exactly which criteria you meet, which you don't, and which need more information. Bring the list to your oncologist.